$69.78
0.10% today
Nasdaq, Nov 03, 04:50 pm CET
ISIN
US05370A1088
Symbol
RNA

Avidity Biosciences Inc Target price 2025 - Analyst rating & recommendation

Avidity Biosciences Inc Classifications & Recommendation:

Buy
95%
Hold
5%

Avidity Biosciences Inc Price Target

Target Price $66.30
Price $69.85
Deviation
Number of Estimates 19
19 Analysts have issued a price target Avidity Biosciences Inc 2026 . The average Avidity Biosciences Inc target price is $66.30. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 22 analysts: 21 Analysts recommend Avidity Biosciences Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Avidity Biosciences Inc stock has an average upside potential 2026 of . Most analysts recommend the Avidity Biosciences Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 10.90 9.72
14.02% 10.85%
EBITDA Margin -3,451.01% -7,025.62%
41.29% 103.58%
Net Margin -2,956.88% -5,579.87%
33.20% 88.71%

16 Analysts have issued a sales forecast Avidity Biosciences Inc 2025 . The average Avidity Biosciences Inc sales estimate is

$9.7m
Unlock
. This is
9.44% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$13.8m 28.57%
Unlock
, the lowest is
$4.9m 54.33%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $10.9m 14.02%
2025
$9.7m 10.85%
Unlock
2026
$20.3m 108.74%
Unlock
2027
$319m 1,470.38%
Unlock
2028
$801m 151.47%
Unlock
2029
$1.3b 58.56%
Unlock
2030
$2.0b 54.80%
Unlock
2031
$2.5b 28.43%
Unlock
2032
$3.0b 17.78%
Unlock

6 Analysts have issued an Avidity Biosciences Inc EBITDA forecast 2025. The average Avidity Biosciences Inc EBITDA estimate is

$-683m
Unlock
. This is
31.60% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-586m 12.91%
Unlock
, the lowest is
$-832m 60.39%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-376m 61.10%
2025
$-683m 81.49%
Unlock
2026
$-741m 8.61%
Unlock
2027
$-380m 48.71%
Unlock

EBITDA Margin

2024 -3,451.01% 41.29%
2025
-7,025.62% 103.58%
Unlock
2026
-3,655.70% 47.97%
Unlock
2027
-119.40% 96.73%
Unlock

18 Avidity Biosciences Inc Analysts have issued a net profit forecast 2025. The average Avidity Biosciences Inc net profit estimate is

$-542m
Unlock
. This is
18.97% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-422m 7.34%
Unlock
, the lowest is
$-741m 62.58%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-322m 51.87%
2025
$-542m 68.23%
Unlock
2026
$-597m 10.09%
Unlock
2027
$-398m 33.28%
Unlock
2028
$-35.2m 91.17%
Unlock
2029
$323m 1,018.45%
Unlock
2030
$682m 111.20%
Unlock
2031
$982m 43.94%
Unlock
2032
$1.2b 24.16%
Unlock

Net Margin

2024 -2,956.88% 33.20%
2025
-5,579.87% 88.71%
Unlock
2026
-2,942.87% 47.26%
Unlock
2027
-125.03% 95.75%
Unlock
2028
-4.39% 96.49%
Unlock
2029
25.43% 679.27%
Unlock
2030
34.70% 36.45%
Unlock
2031
38.89% 12.07%
Unlock
2032
41.00% 5.43%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.89 -4.49
0.69% 55.36%
P/E negative
EV/Sales 927.06

18 Analysts have issued a Avidity Biosciences Inc forecast for earnings per share. The average Avidity Biosciences Inc EPS is

$-4.49
Unlock
. This is
27.92% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.50 0.28%
Unlock
, the lowest is
$-6.13 74.64%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.89 0.69%
2025
$-4.49 55.36%
Unlock
2026
$-4.94 10.02%
Unlock
2027
$-3.30 33.20%
Unlock
2028
$-0.29 91.21%
Unlock
2029
$2.67 1,020.69%
Unlock
2030
$5.65 111.61%
Unlock
2031
$8.13 43.89%
Unlock
2032
$10.09 24.11%
Unlock

P/E ratio

Current -19.90 0.14%
2025
-15.56 21.81%
Unlock
2026
-14.13 9.19%
Unlock
2027
-21.18 49.89%
Unlock
2028
-239.88 1,032.58%
Unlock
2029
26.12 110.89%
Unlock
2030
12.37 52.64%
Unlock
2031
8.59 30.56%
Unlock
2032
6.92 19.44%
Unlock

Based on analysts' sales estimates for 2025, the Avidity Biosciences Inc stock is valued at an EV/Sales of

927.06
Unlock
and an P/S ratio of
1,048.82
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 839.53 123.96%
2025
927.06 10.43%
Unlock
2026
444.13 52.09%
Unlock
2027
28.28 93.63%
Unlock
2028
11.25 60.23%
Unlock
2029
7.09 36.93%
Unlock
2030
4.58 35.40%
Unlock
2031
3.57 22.14%
Unlock
2032
3.03 15.10%
Unlock

P/S ratio

Current 949.80 78.59%
2025
1,048.82 10.43%
Unlock
2026
502.46 52.09%
Unlock
2027
32.00 93.63%
Unlock
2028
12.72 60.23%
Unlock
2029
8.02 36.93%
Unlock
2030
5.18 35.40%
Unlock
2031
4.04 22.14%
Unlock
2032
3.43 15.10%
Unlock

Current Avidity Biosciences Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
TD Cowen
Locked
Locked
Locked Oct 29 2025
Chardan Capital
Locked
Locked
Locked Oct 28 2025
RBC Capital
Locked
Locked
Locked Oct 28 2025
Needham
Locked
Locked
Locked Oct 27 2025
Leerink Partners
Locked
Locked
Locked Oct 27 2025
HC Wainwright & Co.
Locked
Locked
Locked Oct 27 2025
Bernstein
Locked
Locked
Locked Oct 27 2025
Analyst Rating Date
Locked
TD Cowen:
Locked
Locked
Oct 29 2025
Locked
Chardan Capital:
Locked
Locked
Oct 28 2025
Locked
RBC Capital:
Locked
Locked
Oct 28 2025
Locked
Needham:
Locked
Locked
Oct 27 2025
Locked
Leerink Partners:
Locked
Locked
Oct 27 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Oct 27 2025
Locked
Bernstein:
Locked
Locked
Oct 27 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today